The p53–Mdm2 system is key to tumor suppression. We have recently reported that p53 as well as Mdm2 are capable of supporting DNA replication fork progression. On the other hand, we found that Mdm2 is ...

Please provide your email address to receive an email when new articles are posted on . Administration of the MDM2 inhibitor milademetan in an intermittent dosing schedule mitigated dose-limiting ...

Almost half of patients with advanced solid tumors or lymphomas experienced disease control with a drug that reactivates the TP53 tumor suppressor, a first-in-human study showed. Overall, the oral ...

Outside of breast cancer, cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors have not been as successful as tumors develop resistance. New research shows that a murine double minute (MDM2) ...

Over the past two decades, the idea of targeting transcription factors to combat malignancies has turned into a clinical reality. Targeting oncogenes and their interactive partners is an effective ...

Overexpression of c-met as a Prognostic Indicator for Transitional Cell Carcinoma of the Urinary Bladder: A Comparison With p53 Nuclear Accumulation PURPOSE: Testicular germ cell tumors (TGCTs) of ...

Preclinical models highlight the potential of KT-253 as a monotherapy and combined with the standard of care agent venetoclax for the treatment of Acute Myeloid Leukemia (AML) MDM2 degraders shown to ...

Please provide your email address to receive an email when new articles are posted on . Sandra D’Angelo, MD, discussed initial phase 1A/1B data from a clinical trial on the efficacy and safety of ...

This article and associated images are based on a poster originally authored by Sarona Jacob Anderson and presented at ELRIG Drug Discovery 2025 in affiliation with University of Salford. This poster ...

Ocular inflammation uveitis is a serious disease that can destroy eye tissue and cause irreversible blindness. Fortunately, blindness and eye damage can be prevented by suppressing the immune system ...